Cancer Cell:去泛素化酶调节肝炎、纤维化和癌变

2012-06-18 bo 生物谷

6月12日,Cancer Cell杂志报道了去泛素化酶,圆柱瘤病(CYLD)肿瘤抑制因子的失活可引发肝细胞的凋亡、炎症、纤维化和癌症。圆柱瘤病(CYLD)肿瘤抑制因子通过去泛素化上游因子,抑制NFκB和有丝分裂原活化蛋白激酶(MAPK)活化途径。 本研究显示,肝特异性阻断CYLD通过自发的或慢性激活TGF-β活化激酶1(TAK1)和c-Jun N末端激酶(JNK)触发了肝门静脉周边区域肝细胞的死


6月12日,Cancer Cell杂志报道了去泛素化酶,圆柱瘤病(CYLD)肿瘤抑制因子的失活可引发肝细胞的凋亡、炎症、纤维化和癌症。圆柱瘤病(CYLD)肿瘤抑制因子通过去泛素化上游因子,抑制NFκB和有丝分裂原活化蛋白激酶(MAPK)活化途径。

本研究显示,肝特异性阻断CYLD通过自发的或慢性激活TGF-β活化激酶1(TAK1)和c-Jun N末端激酶(JNK)触发了肝门静脉周边区域肝细胞的死亡。随后,肝星形细胞和Kupper细胞活化,进而促进进行性肝纤维化、炎症、肿瘤坏死因子(TNF)产生,以及肝细胞凋亡朝向中央静脉的扩散。在晚些阶段,补偿性增殖导致癌性中心的产生。这些癌性中心特征性地重新表达癌胚肝细胞及干细胞特异性基因。

这些结果证实,CYLD在肝脏作为一种重要肝细胞稳态调节子,通过预防TAK1和JNK不受控的激活,保护着细胞免受自发凋亡之害。

doi:10.1016/j.cell.2011.10.017
PMC:

PMID:

Inactivation of the Deubiquitinase CYLD in Hepatocytes Causes Apoptosis, Inflammation, Fibrosis, and Cancer

Kostas Nikolaou, Ageliki Tsagaratou, Christina Eftychi, George Kollias, George Mosialos, Iannis Talianidis

The tumor suppressor cylindromatosis (CYLD) inhibits the NFκB and mitogen-activated protein kinase (MAPK) activation pathways by deubiquitinating upstream regulatory factors. Here we show that liver-specific disruption of CYLD triggers hepatocyte cell death in the periportal area via spontaneous and chronic activation of TGF-β activated kinase 1 (TAK1) and c-Jun N-terminal kinase (JNK). This is followed by hepatic stellate cell and Kupffer cell activation, which promotes progressive fibrosis, inflammation, tumor necrosis factor (TNF) production, and expansion of hepatocyte apoptosis toward the central veins. At later stages, compensatory proliferation results in the development of cancer foci featuring re-expression of oncofetal hepatic and stem cell-specific genes. The results demonstrate that, in the liver, CYLD acts as an important regulator of hepatocyte homeostasis, protecting cells from spontaneous apoptosis by preventing uncontrolled TAK1 and JNK activation.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1958763, encodeId=ae461958e6350, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Sep 16 01:59:00 CST 2012, time=2012-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780574, encodeId=7fa01e80574cf, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Apr 26 15:59:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868531, encodeId=9eed186853120, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Oct 22 13:59:00 CST 2012, time=2012-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557015, encodeId=e59f155e0158f, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Wed Jun 20 09:59:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575350, encodeId=5f7b15e535024, content=<a href='/topic/show?id=26d83e25254' target=_blank style='color:#2F92EE;'>#去泛素化酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37252, encryptionId=26d83e25254, topicName=去泛素化酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb2c16117221, createdName=mashirong, createdTime=Wed Jun 20 09:59:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
    2012-09-16 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1958763, encodeId=ae461958e6350, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Sep 16 01:59:00 CST 2012, time=2012-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780574, encodeId=7fa01e80574cf, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Apr 26 15:59:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868531, encodeId=9eed186853120, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Oct 22 13:59:00 CST 2012, time=2012-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557015, encodeId=e59f155e0158f, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Wed Jun 20 09:59:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575350, encodeId=5f7b15e535024, content=<a href='/topic/show?id=26d83e25254' target=_blank style='color:#2F92EE;'>#去泛素化酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37252, encryptionId=26d83e25254, topicName=去泛素化酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb2c16117221, createdName=mashirong, createdTime=Wed Jun 20 09:59:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1958763, encodeId=ae461958e6350, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Sep 16 01:59:00 CST 2012, time=2012-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780574, encodeId=7fa01e80574cf, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Apr 26 15:59:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868531, encodeId=9eed186853120, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Oct 22 13:59:00 CST 2012, time=2012-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557015, encodeId=e59f155e0158f, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Wed Jun 20 09:59:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575350, encodeId=5f7b15e535024, content=<a href='/topic/show?id=26d83e25254' target=_blank style='color:#2F92EE;'>#去泛素化酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37252, encryptionId=26d83e25254, topicName=去泛素化酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb2c16117221, createdName=mashirong, createdTime=Wed Jun 20 09:59:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1958763, encodeId=ae461958e6350, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Sep 16 01:59:00 CST 2012, time=2012-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780574, encodeId=7fa01e80574cf, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Apr 26 15:59:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868531, encodeId=9eed186853120, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Oct 22 13:59:00 CST 2012, time=2012-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557015, encodeId=e59f155e0158f, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Wed Jun 20 09:59:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575350, encodeId=5f7b15e535024, content=<a href='/topic/show?id=26d83e25254' target=_blank style='color:#2F92EE;'>#去泛素化酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37252, encryptionId=26d83e25254, topicName=去泛素化酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb2c16117221, createdName=mashirong, createdTime=Wed Jun 20 09:59:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
    2012-06-20 axin014
  5. [GetPortalCommentsPageByObjectIdResponse(id=1958763, encodeId=ae461958e6350, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Sep 16 01:59:00 CST 2012, time=2012-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780574, encodeId=7fa01e80574cf, content=<a href='/topic/show?id=517a4016ac' target=_blank style='color:#2F92EE;'>#cancer cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4016, encryptionId=517a4016ac, topicName=cancer cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=96f62500201, createdName=12498e67m28暂无昵称, createdTime=Fri Apr 26 15:59:00 CST 2013, time=2013-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1868531, encodeId=9eed186853120, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Oct 22 13:59:00 CST 2012, time=2012-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1557015, encodeId=e59f155e0158f, content=<a href='/topic/show?id=154be128170' target=_blank style='color:#2F92EE;'>#癌变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71281, encryptionId=154be128170, topicName=癌变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd7914850828, createdName=axin014, createdTime=Wed Jun 20 09:59:00 CST 2012, time=2012-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1575350, encodeId=5f7b15e535024, content=<a href='/topic/show?id=26d83e25254' target=_blank style='color:#2F92EE;'>#去泛素化酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37252, encryptionId=26d83e25254, topicName=去泛素化酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb2c16117221, createdName=mashirong, createdTime=Wed Jun 20 09:59:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]

相关资讯

Cancer:针灸预防头颈肿瘤放疗后患者口干

MedSci评:针灸,中医类文章,只要研究得当,证据充分,同样可以发表质量非常好的文章。象中医针灸类文章,研究设计环节是文章核心。 作者:复旦大学新闻中心驻地记者孙国根 通讯员 倪洪珍 来源:医学论坛网     刚刚闭幕的复旦大学附属肿瘤医首届国际针灸治疗肿瘤论坛披露,针灸被现代循证医学证实对预防头颈部肿瘤病人放疗后的口干症状效果显著,该成果已被国际顶尖肿瘤杂志Cancer收录